Nektar's atopic dermatitis drug data published in The Lancet

August 25, 2026 8:30 AM

Nektar Therapeutics (Nasdaq: NKTR) announced the publication of Phase 2b trial results for its drug candidate rezpegaldesleukin in The Lancet ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found